Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
insitro, a biotech company in South San Francisco, seeks a senior finance leader to build and run FP&A, advancing an AI-enabled finance capability. You will own the company-wide budget, headcount model, and financial materials for the Executive Team and Board, presenting to the Board.
Based in South San Francisco, this role reports to the CFO, leads the FP&A team, and offers a hybrid schedule of three days per week on average.
insitro is looking for a senior finance leader to build and run our FP&A function, and to take what is already an AI-forward finance capability into the next generation of FP&A. We've done the work of embedding AI across finance; this role owns taking that foundation further so the business has seamless access to information and makes faster, better-informed decisions.
Your year-one priorities: move us from a bi-annual budget to a rolling quarterly forecast; make scenario planning routine enough that the Executive Team sees the budget impact of a decision in days, not weeks; extend our AI-enabled, self-serve FP&A capability; and tighten the partnership with Accounting so planning, close, and reporting run as one system.
You’ll own the company-wide budget and forecast, the headcount and compensation model, and the financial materials for the Executive Team and Board, and you’ll present directly to the Board. You’ll partner closely with Research, Platform, Clinical Development, People, and G&A, serve as a standing partner to Accounting leadership, and work tightly with Investor Relations, Corporate Strategic Finance, and Corporate Development to keep the internal plan and the external financial narrative consistent.
Based in South San Francisco, this position reports to the CFO, leads the FP&A team (today, our Director of R&D and Clinical FP&A), and offers an in-person hybrid schedule of three days per week, on average.
Planning, Forecasting & Scenario Analysis
Next-Generation FP&A & Finance Systems
Business & Accounting Partnership
Leadership, Board & Investor Relations
Experience & Qualifications
Core Competencies
Preferred Qualifications
Our target starting salary for successful US-based applicants for this role is $300,000-$345,000. To determine starting pay, we consider multiple job-related factors including a candidate's skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data.
This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.
In addition, insitro also provides our employees:
insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.
We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.
#LI-Hybrid
About insitro
insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com.